Hepatitis virus infection is a major public health problem worldwide. Currently, Brazil has almost 700,000 cases. The Brazilian Unified Health System (SUS) provides therapeutic regimens for people infected with hepatitis C virus (HCV). We determined the clinical, laboratory, epidemiologic, and geospatial characteristics of patients infected with HCV treated with second-generation direct-action antivirals (DAAs) in a hospital reference center in São Paulo state, Brazil, using data from file records. A map was constructed using a geographic information system. From 2015 to 2018, 197 individuals received second-generation DAAs (mean age, 57.68 ± 1.36 years; interquartile range, 56.22–59.14 years; 58.9% male; 41.1% female). Genotypes 1a and 1b accounted for 75.7% of cases and the prevalent therapeutic regimen was sofosbuvir/simeprevir. Sustained viral response accounted for 98.9% and the METAVIR score F3/F4 for 50.8%. Increased alanine transferase was significantly correlated with an increase in α-fetoproteins (p = 0.01), and severe necro-inflammatory activity (p = 0.001). Associated comorbidities were found in 71.6%, mainly coronary artery and gastrointestinal disorders. The cumulative incidence in the region was 2.6 per 10,000 inhabitants. Our data highlight the role of reference hospitals in Brazil’s public health system in the treatment of HCV. Low incidence rates demonstrated the fragility of municipalities in the active search for patients.

中文翻译：

---

在巴西圣保罗州中部地区的参考中心，使用第二代直接作用抗病毒药物治疗的丙型肝炎病毒感染患者的临床，流行病学和地理空间特征

肝炎病毒感染是世界范围内的主要公共卫生问题。目前，巴西有近70万例。巴西统一卫生系统（SUS）为感染丙型肝炎病毒（HCV）的人提供治疗方案。我们使用文件记录中的数据，确定了在巴西圣保罗州一家医院参考中心中接受第二代直接作用抗病毒药物（DAA）治疗的HCV感染患者的临床，实验室，流行病学和地理空间特征。使用地理信息系统绘制了地图。从2015年到2018年，有197位患者接受了第二代DAA（平均年龄为57.68±1.36岁；四分位间距为56.22-59.14岁；男性为58.9％；女性为41.1％）。基因型1a和1b占病例的75.7％，目前的治疗方案为sofosbuvir / simeprevir。持续的病毒应答占98.9％，METAVIR得分F3 / F4占50.8％。丙氨酸转移酶的增加与甲胎蛋白的增加显着相关（p = 0.01）和严重的坏死性炎症活动（p = 0.001）。相关合并症占71.6％，主要是冠状动脉疾病和胃肠道疾病。该地区的累积发病率为每10,000居民2.6。我们的数据强调了巴西公共卫生系统中参考医院在HCV治疗中的作用。低发病率表明市政当局在积极寻找患者方面脆弱。